Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation.

OBJECTIVE Neuroimaging findings have identified lower cortical gray matter volume in schizophrenia. Apoptosis (programmed cell death) has been proposed as a contributing pathophysiological mechanism. Levels of antiapoptotic Bcl-2 protein are low in the temporal cortex of schizophrenia patients. Bcl-2 interacts with the proapoptotic Bax protein at an upstream checkpoint to regulate the activation of apoptosis by caspase-3 and other proteolytic caspase proteins. A high Bax/Bcl-2 ratio is associated with greater vulnerability to apoptotic activation, while a high caspase-3 level is often associated with apoptotic activity. It was hypothesized that the Bax/Bcl-2 ratio, but not caspase-3, would be high in the temporal cortex of patients with chronic schizophrenia. METHOD Bax, Bcl-2, and caspase-3 proteins were measured by semiquantitative Western blot in Brodmann's area 21 (middle temporal gyrus) of postmortem tissue from patients with schizophrenia (N=15), bipolar disorder (N=15), or major depression (N=15) and nonpsychiatric comparison subjects (N=15). RESULTS The Bax/Bcl-2 ratio was 50% higher in the schizophrenia patients than the nonpsychiatric comparison subjects. The level of caspase-3 (inactive zymogen and activated subunits) was not significantly different. CONCLUSIONS The higher Bax/Bcl-2 ratio suggests that cortical cells are vulnerable to apoptosis in chronic schizophrenia. However, the normal caspase-3 level suggests that apoptosis is not active in this illness phase. Furthermore, the results appear to distinguish the pathophysiology of schizophrenia from most classic neurodegenerative disorders, in which postmortem caspase-3 levels are high. Further studies are needed to investigate the implications of abnormal apoptotic proteins in schizophrenia.

[1]  E. Alnemri,et al.  In vitro activation of CPP 32 and Mch 3 by Mch 4 , a novel human apoptotic cysteine protease containing two FADD-like domains ( granzyme B / Mch 2 / protease cascade / FAS / APO-I-receptor ) , 2005 .

[2]  DNA fragmentation decreased in schizophrenia but not bipolar disorder. , 2003, Archives of general psychiatry.

[3]  R. Kikinis,et al.  Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. , 2003, The American journal of psychiatry.

[4]  Eve C. Johnstone,et al.  Structural Gray Matter Differences between First-Episode Schizophrenics and Normal Controls Using Voxel-Based Morphometry , 2002, NeuroImage.

[5]  C. Leeuwenburgh,et al.  The Role of Apoptosis in the Normal Aging Brain, Skeletal Muscle, and Heart , 2002, Annals of the New York Academy of Sciences.

[6]  R. Kahn,et al.  Volume changes in gray matter in patients with schizophrenia. , 2002, The American journal of psychiatry.

[7]  Pat Levitt,et al.  Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse , 2001, Trends in Neurosciences.

[8]  R. McCarley,et al.  A review of MRI findings in schizophrenia , 2001, Schizophrenia Research.

[9]  J. Lieberman,et al.  Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain , 2001, Schizophrenia Research.

[10]  B. Citron,et al.  Plasticity and stabilization of neuromuscular and CNS synapses: interactions between thrombin protease signaling pathways and tissue transglutaminase. , 2001, International review of cytology.

[11]  Junying Yuan,et al.  Apoptosis in the nervous system , 2000, Nature.

[12]  J. Lieberman,et al.  Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia , 2000, Biological Psychiatry.

[13]  R. Yolken,et al.  The Stanley Foundation brain collection and Neuropathology Consortium , 2000, Schizophrenia Research.

[14]  E. Hirsch,et al.  Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Gilmore,et al.  Developmental expression of Bcl-2 protein in human cortex. , 2000, Brain research. Developmental brain research.

[16]  Jeffrey A Lieberman,et al.  Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective , 1999, Biological Psychiatry.

[17]  B. Roth,et al.  Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗ ∗ See accompanying Editorial, in this issue. , 1999, Biological Psychiatry.

[18]  E. Masliah,et al.  Caspase Dependent DNA Fragmentation Might Be Associated with Excitotoxicity in Alzheimer Disease , 1998, Journal of neuropathology and experimental neurology.

[19]  M. Mattson,et al.  Evidence for Synaptic Apoptosis , 1998, Experimental Neurology.

[20]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[21]  Tyrone D. Cannon,et al.  A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. , 1998, Archives of general psychiatry.

[22]  E. Bullmore,et al.  Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. , 1997, The American journal of psychiatry.

[23]  N. Cairns,et al.  Aberrant expression of bcl-2 gene family in Down's syndrome brains. , 1997, Brain research. Molecular brain research.

[24]  L. DeLisi,et al.  Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia , 1997, Psychiatry Research: Neuroimaging.

[25]  D. Lewis,et al.  Development of the Prefrontal Cortex during Adolescence: Insights into Vulnerable Neural Circuits in Schizophrenia , 1997, Neuropsychopharmacology.

[26]  M. Raichle,et al.  Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.

[27]  R. Gascoyne,et al.  Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. , 1997, Cancer research.

[28]  J. Gilmore,et al.  Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia , 1997, Schizophrenia Research.

[29]  L. Rubin,et al.  Bax promotes neuronal cell death and is downregulated during the development of the nervous system. , 1997, Development.

[30]  C. Cotman,et al.  Bax Protein Expression Is Increased in Alzheimer's Brain: Correlations with DNA Damage, Bcl‐2 Expression, and Brain Pathology , 1997, Journal of neuropathology and experimental neurology.

[31]  A. LeBlanc,et al.  Amyloid β Peptide of Alzheimer’s Disease Downregulates Bcl-2 and Upregulates Bax Expression in Human Neurons , 1996, The Journal of Neuroscience.

[32]  S. Srinivasula,et al.  In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Y. Ben-Ari,et al.  Apoptotic features of selective neuronal death in ischemia, epilepsy and gpI20 toxicity , 1996, Trends in Neurosciences.

[34]  Obstetric complications and schizophrenia: A meta-analysis , 1996, Schizophrenia Research.

[35]  D. Bredesen.  Neural apoptosis , 1995, Annals of neurology.

[36]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[37]  Robert M. Post,et al.  Programmed cell death: Implications for neuropsychiatric disorders , 1994, Biological Psychiatry.

[38]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[39]  R. Oppenheim.  Cell death during development of the nervous system. , 1991, Annual review of neuroscience.

[40]  J. Kelsoe,et al.  Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. , 1989, The American journal of psychiatry.

[41]  L. Brain.  The Nervous System , 1963, Nature.